Summit Global Investments Reduces Position in United Therapeutics Co. (NASDAQ:UTHR)

Summit Global Investments trimmed its holdings in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 27.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 36,081 shares of the biotechnology company's stock after selling 13,918 shares during the period. United Therapeutics accounts for 0.8% of Summit Global Investments' holdings, making the stock its 25th largest position. Summit Global Investments owned 0.08% of United Therapeutics worth $12,731,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the stock. Signaturefd LLC lifted its position in shares of United Therapeutics by 4.7% during the 4th quarter. Signaturefd LLC now owns 663 shares of the biotechnology company's stock valued at $234,000 after acquiring an additional 30 shares during the period. Parallel Advisors LLC lifted its holdings in shares of United Therapeutics by 2.8% during the 4th quarter. Parallel Advisors LLC now owns 1,090 shares of the biotechnology company's stock worth $385,000 after acquiring an additional 30 shares during the period. Great Lakes Advisors LLC boosted its position in shares of United Therapeutics by 1.6% during the 4th quarter. Great Lakes Advisors LLC now owns 1,974 shares of the biotechnology company's stock worth $697,000 after acquiring an additional 31 shares in the last quarter. Oregon Public Employees Retirement Fund increased its stake in United Therapeutics by 0.4% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 9,108 shares of the biotechnology company's stock valued at $3,214,000 after acquiring an additional 33 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC raised its position in United Therapeutics by 0.8% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 4,913 shares of the biotechnology company's stock valued at $1,761,000 after purchasing an additional 39 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company's stock.

Remove Ads

Insider Transactions at United Therapeutics

In related news, Director Nilda Mesa sold 255 shares of the business's stock in a transaction dated Monday, December 30th. The shares were sold at an average price of $355.77, for a total value of $90,721.35. Following the transaction, the director now directly owns 5,528 shares of the company's stock, valued at approximately $1,966,696.56. The trade was a 4.41 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Michael Benkowitz sold 10,000 shares of the stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $360.76, for a total transaction of $3,607,600.00. Following the transaction, the chief operating officer now directly owns 2,577 shares of the company's stock, valued at $929,678.52. This represents a 79.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 80,255 shares of company stock valued at $28,995,021 over the last three months. Corporate insiders own 11.90% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on UTHR shares. HC Wainwright reiterated a "buy" rating and issued a $425.00 price target on shares of United Therapeutics in a research note on Thursday, February 27th. StockNews.com lowered shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Thursday, February 27th. Finally, UBS Group raised their target price on shares of United Therapeutics from $415.00 to $475.00 and gave the company a "buy" rating in a research report on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat.com, United Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $388.25.

United Therapeutics Stock Performance

United Therapeutics stock traded down $6.53 during mid-day trading on Tuesday, reaching $313.34. The stock had a trading volume of 58,778 shares, compared to its average volume of 446,533. United Therapeutics Co. has a fifty-two week low of $221.53 and a fifty-two week high of $417.82. The stock's 50-day simple moving average is $344.24 and its 200-day simple moving average is $356.84. The firm has a market capitalization of $14.07 billion, a PE ratio of 13.76, a price-to-earnings-growth ratio of 0.97 and a beta of 0.64.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.10 by $0.09. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The business had revenue of $735.90 million during the quarter, compared to the consensus estimate of $734.74 million. During the same quarter last year, the firm posted $4.36 EPS. On average, research analysts forecast that United Therapeutics Co. will post 24.48 earnings per share for the current fiscal year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.